ANDA 214402, held by Hikma Pharmaceuticals. Cefepime Hydrochloride.
As of Nov 21, 2026, ANDA 214402 (Cefepime Hydrochloride), held by Hikma Pharmaceuticals, was first approved by FDA on May 22, 2024, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 22, 2024 | Original application | Approved | None posted |
| Cefepime HydrochlorideEQ 1GM BASE/VIAL · injectable;injection | Cefepime Hydrochloride | Rx |
| Cefepime HydrochlorideEQ 2GM BASE/VIAL · injectable;injection | Cefepime Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters